目的 探討三子止咳膠囊聯(lián)合布地奈德粉吸入劑治療慢性阻塞性肺疾病穩(wěn)定期的臨床療效。方法 選擇2017年5月-2018年11月在濮陽(yáng)市人民醫(yī)院就診的82例慢性阻塞性肺疾病患者作為研究對(duì)象，按照隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各41例。對(duì)照組霧化吸入布地奈德粉吸入劑，1吸/次，2次/d。治療組在對(duì)照組治療的基礎(chǔ)上口服三子止咳膠囊，0.6 g/次，3次/d。兩組患者連續(xù)治療3個(gè)月。觀察兩組的臨床療效，比較兩組的肺功能、炎癥因子。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為82.93%、95.12%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的第一秒用力呼氣容積（FEV1）、FEV1/用力肺活量（FVC）、最大呼氣流速（PEF）、FEV1預(yù)計(jì)值均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組的FEV1、FEV1/FVC、PEF、FEV1預(yù)計(jì)值均明顯高于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的C反應(yīng)蛋白（CRP）、細(xì)胞間黏附分子-1（ICAM-1）、腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-17（IL-17）水平均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組的CRP、ICAM-1、TNF-α、IL-17水平均明顯低于對(duì)照組，兩組差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 三子止咳膠囊聯(lián)合布地奈德粉吸入劑治療慢性阻塞性肺疾病穩(wěn)定期具有較好的臨床療效，能改善患者的肺功能，減輕炎癥反應(yīng)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Sanzi Zhike Capsules combined with Budesonide Powder for inhalation in treatment of stable chronic obstructive pulmonary disease. Methods Patients (82 cases) with stable chronic obstructive pulmonary disease in Puyang People's Hospital from May 2017 to November 2018 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were atomization inhalation administered with Budesonide Powder for inhalation, 1 suction/time, twice daily. Patients in the treatment group were po administered with Sanzi Zhike Capsules on the basis of the control group, 0.6 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and pulmonary function and inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.93% and 95.12%, respectively, and there was difference between two groups (P < 0.05). After treatment, FEV1, FEV1/FVC, PEF, and FEV1 predicted in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the pulmonary function indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of CRP, ICAM-1, TNF-α, and IL-17 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the inflammatory factors indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Sanzi Zhike Capsules combined with Budesonide Powder for inhalation has clinical curative effect in treatment of stable chronic obstructive pulmonary disease, can improve the lung function of patients and reduce the inflammatory reaction, which has a certain clinical application value.

R974